Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mainstay Medical Wins First ReActiv8 Neurostimulation Implant Sale

Executive Summary

Mainstay Medical has sold its first ReActiv8 neurostimulator implant in Germany. The implant was performed by an orthopedic surgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz, Germany.

You may also be interested in...



Mainstay Medical Reaches Milestone With Interim Results Of US Clinical Trial

Mainstay Medical is making steps towards the US commercialization of its neurostimulation system ReActiv8. The company announced a positive outcome from interim analysis of its US ReActiv8 B clinical trial which aims to gather data in support of an application for pre-market approval from the US FDA.

INS 2017: Neuromodulation's Future Features Innovative Power Source, Materials And Treatment Protocols

Neuromodulation technology is advancing at breakneck speed, as physicians, academic, and industry innovators deepen their understanding of the field and learn what works and what doesn't. At the Innovations Day held during the 13th world congress of the International Neuromodulation Society in Edinburgh, Scotland, Medtech Insight highlights the notable new techs that are in the pipeline of emerging companies.

Mainstay Set To Launch ReActiv8 Neurostimulator In Germany

Mainstay Medical is ready to launch its ReActiv8 neurostimulator, starting in Germany, now that the implantable device has a CE mark for the treatment of chronic back pain, the company announced May 25.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT104383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel